Peritubular capillary rarefaction and lymphangiogenesis in chronic allograft failure

Transplantation

Volumn 83, Issue 12, 2007, Pages 1542-1550

  Adair, Anya ^a   Mitchell, David R ^a   Kipari, Tiina ^a   Qi, Feng ^a   Bellamy, Christopher O C ^b   Robertson, Faye ^c   Hughes, Jeremy ^a   Marson, Lorna P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Endothelium; Kidney; Macrophage; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYTOKINE; GROWTH FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LYMPHANGIOGENIC GROWTH FACTOR; PREDNISOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; KIDNEY CARCINOMA; KIDNEY CORTEX; KIDNEY MEDULLA; LYMPH VESSEL; LYMPHANGIOGENESIS; MALE; MICROVASCULATURE; NEPHRECTOMY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CAPILLARIES; FEMALE; HUMANS; LYMPHANGIOGENESIS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34250796179     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000266689.93615.cd     Document Type: Article

References (45)

1. Ponticelli C, Villa M, Cesana B, et al. Risk factors for late kidney allograft failure. Kidney Int 2002; 62: 1848.
2. Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 2006; 16: 148.
3. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
4. Morozumi K, Oikawa T, Fukuda M, et al. Diagnosis of chronic rejection using peritubular and glomerular capillary lesions. Transplant Proc 1996; 28: 508.
5. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
6. Fine LG, Orphanides C, Norman JT. Progressive renal disease: The chronic hypoxia hypothesis. Kidney Int Suppl 1998; 65: S74.
7. Kerjaschki D, RegeleHM,Moosberger I, et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004; 15: 603.
8. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999; 154: 385.
9. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144: 789.
10. Ozdemir BH, Demirhan B, Gungen Y. The presence and prognostic importance of glomerular macrophage infiltration in renal allografts. Nephron 2002; 90: 442.
11. Pilmore HL, Painter DM, Bishop GA, et al. Early up-regulation of macrophages and myofibroblasts: A new marker for development of chronic renal allograft rejection. Transplantation 2000; 69: 2658.
12. Furuichi K, Wada T, Iwata Y, et al. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol 2003; 14: 2503.
13. Furuichi K, Gao JL, Murphy PM. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol 2006; 169: 372.
14. Nagano H, Nadeau KC, Kusaka M, et al. Infection-associated macrophage activation accelerates chronic renal allograft rejection in rats. Transplantation 1997; 15: 1602.
15. Ohashi R, Kitamura H, Yamanaka N. Peritubular capillary injury during the progression of experimental glomerulonephritis in rats. J Am Soc Nephrol 2000; 11: 47.
16. Duffield JS, Tipping PG, Kipari T, et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005; 167: 1207.
17. Kipari T, Cailhier JF, Ferenbach D, et al. Nitric oxide is an important mediator of renal tubular epithelial cell death in vitro and in murine experimental hydronephrosis. Am J Pathol 2006; 169: 388.
18. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
19. Fox SB, Leek RD, Weekes MP, et al. Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995; 177: 275.
20. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A: 2474.
21. Ishii Y, Sawada T, Kubota K, et al. Loss of peritubular capillaries in the development of chronic allograft nephropathy. Transplant Proc 2005; 37: 981.
22. Kang DH, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806.
23. Bohle A, Mackensen-Haen S, Wehrmann M. Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res 1996; 19: 191.
24. Choi YJ, Chakraborty S, Nguyen V, et al. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: Altered expression of vascular endothelial growth factor. Hum Pathol 2000; 31: 1491.
25. Ozdemir BH, Ozdemir FN, Gungen Y, Haberal M. Role of macrophages and lymphocytes in the induction of neovascularization in renal allograft rejection. Am J Kidney Dis 2002; 39: 347.
26. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001; 12: 1434.
27. Kang DH, Hughes J, Mazzali M, et al. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001; 12: 1448.
28. Jose MD, Ikezumi Y, van Rooijen N, et al. Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation 2003; 76: 1015.
29. Diamond JR. Macrophages and progressive renal disease in experimental hydronephrosis. Am J Kidney Dis 1995; 26: 133.
30. Azuma H, Nadeau KC, Ishibashi M, Tilney NL. Prevention of functional, structural, and molecular changes of chronic rejection of rat renal allografts by a specific macrophage inhibitor. Transplantation 1995; 60: 1577.
31. Wyburn KR, Jose MD, Wu H, et al. The role of macrophages in allograft rejection. Transplantation 2005; 80: 1641.
32. Duffield JS, Erwig L-P, Wei X-q, et al. Activated Macrophages Direct Apoptosis and Suppress Mitosis of Mesangial Cells. J Immunol 2000; 164: 2110.
33. Duffield JS, Ware CF, Ryffel B, Savill J. Suppression by Apoptotic Cells Defines Tumor Necrosis Factor-Mediated Induction of Glomerular Mesangial Cell Apoptosis by Activated Macrophages. Am J Pathol 2001; 159: 1397.
34. Albrecht EW, Stegeman CA, Tiebosch AT, et al. Expression of inducible and endothelial nitric oxide synthases, formation of peroxynitrite and reactive oxygen species in human chronic renal transplant failure. Am J Transplant 2002; 2: 448.
35. Joles JA, Vos IH, Grone HJ, Rabelink TJ. Inducible nitric oxide synthase in renal transplantation. Kidney Int 2002; 61: 872.
36. Vos IH, Joles JA, Schurink M, et al. Inhibition of inducible nitric oxide synthase improves graft function and reduces tubulointerstitial injury in renal allograft rejection. Eur J Pharmacol 2000; 391: 31.
37. Albrecht EW, van Goor H, Tiebosch AT, et al. Nitric oxide production and nitric oxide synthase expression in acute human renal allograft rejection. Transplantation 2000; 70: 1610.
38. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113: 1040.
39. El-Obeid A, Sunnuqrut N, Hussain A, et al. Immature B cell malignancies synthesize VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (KDR). Leuk Res 2004; 28: 133.
40. Bairey O, Boycov O, Kaganovsky E, et al. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 2004; 28: 243.
41. Ruddell A, Mezquita P, Brandvold KA, et al. B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am J Pathol 2003; 163: 2233.
42. Kadowaki I, Ichinohasama R, Harigae H, et al. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Haematol 2005; 130: 869.
43. Reinders ME, Sho M, Izawa A, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112: 1655.
44. Angeli V, Ginhoux F, Llodra J, et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 2006; 24: 203.
45. Pilmore HL, Eris JM, Painter DM, et al. Vascular endothelial growth factor expression in human chronic renal allograft rejection. Transplantation 1999; 67: 929.